Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | PPIB | P23284 | 1/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15886556 | 1.00 | NPC1 (0.74) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL11761142 | 0.92 | NPC1 (0.82) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL9416606 | 0.92 | NPC1 (0.82) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL12604611 | 0.87 | EPHX2 (0.78) | RAB9ASMN1; SMN2EPHX2KMT2AMEN1 | |
| SCHEMBL18868425 | 0.87 | EPHX2 (0.78) | RAB9ASMN1; SMN2EPHX2KMT2AMEN1 | |
| SCHEMBL25442568 | 0.86 | NPC1 (0.74) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL12215290 | 0.86 | NPC1 (0.74) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL5863585 | 0.86 | NPC1 (0.74) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL9977905 | 0.86 | ALDH1A1 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2EPHX2 | |
| Hydrochloric Acid SCHEMBL30918901 | 0.85 | EPHX2 (0.76) | RAB9ASMN1; SMN2EPHX2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100372532-C | Imidazolin-2-ylaminophenyl amides as IP antagonists. | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | CN | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| CN-1780617-A | Imidazolin-2-ylaminophenyl amides as IP antagonists. | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622611-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | NPC1 2964/4885RAB9A 2168/4885ALDH1A1 2894/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | NPC1 2353/4885RAB9A 2946/4885ALDH1A1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.